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In this work, a platform was developed and tested to allow to detect a variety of candidate
viral, bacterial and parasitic pathogens, for acute fever of unknown origin. The platform is
based on a centrifugal microfluidic cartridge, the LabDisk (“FeverDisk” for the specific appli-
cation), which integrates all necessary reagents for sample-to-answer analysis and is pro-
cessed by a compact, point-of-care compatible device.
Methodology/Principal findings
A sample volume of 200 μL per FeverDisk was used. In situ extraction with pre-stored
reagents was achieved by bind-wash-elute chemistry and magnetic particles. Enzymes for
the loop-mediated isothermal amplification (LAMP) were pre-stored in lyopellet form provid-
ing stability and independence from the cold chain. The total time to result from sample inlet
to read out was 2 h. The proof-of-principle was demonstrated in three small-scale feasibility
studies: in Dakar, Senegal and Khartoum, Sudan we tested biobanked samples using 29
and 9 disks, respectively; in Reinfeld, Germany we tested spiked samples and analyzed the
limit of detection using three bacteria simultaneously spiked in whole blood using 15 disks.
Overall during the three studies, the FeverDisk detected dengue virus (different serotypes),
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Conclusions/Significance
The FeverDisk proved to be universally applicable as it successfully detected all different
types of pathogens as single or co-infections, while it also managed to define the serotype
of un-serotyped dengue samples. Thirty-eight FeverDisks at the two African sites provided
59 assay results, out of which 51 (86.4%) were confirmed with reference assay results. The
results provide a promising outlook for future implementation of the platform in larger pro-
spective clinical studies for defining its clinical sensitivity and specificity. The technology
aims to provide multi-target diagnosis of the origins of fever, which will help fight lethal dis-
eases and the incessant rise of antimicrobial resistance.
Author summary
Infectious diseases in tropical regions may have a variety of viral, bacterial or parasitic ori-
gins and a patient may suffer from several diseases simultaneously, each presenting with
acute fever as a clinical symptom. This makes it difficult to determine the origin of the
pathogen causing the disease(s). In addition to the endemic infectious diseases, outbreaks
of epidemics frequently complicate diagnostic demands. Accurate diagnosis for proper
patient management requires the utilization of highly sensitive and specific, rapid, easy-
to-use diagnostic tools compatible with point-of-care settings. We describe the use of a
disk-shaped microfluidic platform, the “FeverDisk”, for differential diagnosis of acute
fever. Our FeverDisk platform demonstrated its capability to detect bacteria, viruses and
parasites that are typical of tropical single and co-infections from biobanked samples
within only 2 hours and in very good agreement with reference method results. This, in
combination with its easy-to-use and point-of-care compatible nature, render our plat-
form a promising candidate for detection of tropical diseases and precise identification of
the cause of acute fever, in endemic and epidemic settings. Future work will involve exten-
sive clinical characterization of the platform in prospective studies.
Introduction
Acute fever is a common symptom observed in patients suffering from infectious diseases [1].
There is a broad range of infections that may cause acute fever. Some of them are accompanied
by localized symptoms, e.g. respiratory tract, urinary tract, gastrointestinal infections, while
others not, in which case it is termed as non-specific fever, or fever of unknown origin. The lat-
ter group of infections frequently occurs in tropical areas. A main cause (etiology) of non-spe-
cific fever is Plasmodium spp, which, despite the intense efforts and remarkable progress for its
eradication, was responsible for 219 million new cases and 435,000 deaths reported globally in
2017, the vast majority of which (90%) were reported in the Sub-Saharan African region [2].
Recent studies investigated the etiologies of fever and found a broad range of unspecific, non-
malaria febrile diseases present [3–7]. Therefore, accurate diagnosis becomes a challenge in
this complicated epidemiological landscape due to the occurrence of co-infections (e.g.
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salmonellosis and malaria [8]), lack of accurate, specific and sensitive tools, and inadequately
trained personnel.
Within this context, febrile illness infections require different patient management given
that a variety of pathogens can cause the diseases. Pathogens include parasites (Plasmodium),
bacteria (Salmonella, Rickettsia or Leptospira) and viruses (dengue, chikungunya or Zika
virus). Thus, the misinterpretation of non-specific fever and the practice of solely empirical
diagnoses can lead to inadequate treatment, resulting in high risk of mortality, continued dis-
ease transmission and increased antimicrobial resistance [9].
Several state-of-the-art methods are currently being implemented for the diagnosis of
fever-related diseases, including microscope examination of stained thick and thin blood
smears, and Lateral Flow Tests (LFTs) for malaria [10–12] and non-malaria diseases [13–15].
However, the former may be error-prone due to the subjective interpretation of the results
as it depends on the experience of the personnel to see the parasite by eye when using the
microscope. The latter, despite being cheap and easy-to-use, also depends on the subjective
opinion of the user during the visual read out, especially when the test line of the LFT is not
sharply distinguishable. Furthermore, studies have shown that both methods can lack suffi-
cient sensitivity [15–18].
Bacterial and viral culture are also used, but both are labour-intensive, time-consuming and
not easy to perform, requiring sophisticated laboratory equipment and qualified staff.
To facilitate accurate species identification, nucleic acid amplification technologies
(NAATs), such as PCR or isothermal amplification methods, need to be used [19]. These
methods are in general more specific, suitable for a large number of diseases, and have been
integrated in some point-of-care (POC) or near-patient systems already on the market or in
near-commercialization phase, such as the GeneXpert, FilmArray, ID NOW, cobas Liat, Liai-
son MDX, GenePOC. Most of them provide various degrees of multiplexity, time-to-result,
and integration, as reviewed by Mitsakakis/D’Acremont et al [20], but do not usually cover the
malaria/non-malaria febrile illness panel.
In contrast, the VerePLEX Biosystem (Veredus Laboratories) [21] incorporates the Vere-
Trop [22] capable for multi-pathogen detection of tropical diseases. However, it is limited by
the high cost of cartridges (100 USD) [23] and the use of two units for diagnosis, one for PCR
and hybridization, and one for detection. It requires an ex situ sample preparation and the
overall time-to-result is 3.5 h. The Q-POC (QuantuMDx) [24] is a portable apparatus at pre-
market stage and its first applications are in malaria species subtyping [25] but there is no pub-
lished evidence for multi-disease detection as yet.
This study addresses the challenges for the technologies and their applications discussed
above. We have developed a system for detecting a 12-plex panel of fever-causing pathogens
called “FeverDisk”, which is based on the centrifugal microfluidic platform LabDisk [26]. The
FeverDisk features fully-automated integrated sample preparation with downstream Loop-
mediated isothermal amplification (LAMP) [27, 28], allowing a time-to-result of 70–120 min
for the individual assays in a 120 min total run-time window with minimum hands-on time of
~5 min, for pipetting the sample into the cartridge. The selected pathogen panel, whose spe-
cific primers were used in the FeverDisk for feasibility demonstration, included: Plasmodium
falciparum (Pf), P. vivax (Pv), P. ovale (Po), P. malariae (Pm); Salmonella enterica Typhi (ST),
S. enterica Paratyphi A (SPa), Streptococcus pneumoniae (Spn), chikungunya virus (CHIKV),
dengue virus—serotypes 1–4 (DENV1-4), and Zika virus (ZIKV). The developed assays to
detect these pathogens also included the pan-malaria, Plasmodium species (Pspp) assay. This is
a non-exhaustive list of fever-related pathogens that could potentially be detected on the plat-
form. The combination of the target pathogens was selected among many others [20] for feasi-
bility demonstration with the criteria to include: (i) the three main types of pathogens, namely,
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bacteria, viruses and parasites; (ii) vector-borne diseases; and (iii) bacterial diseases that are
common in tropical areas and associated with antimicrobial resistance.
Due to the limited access time at the two African sites (both reference centers, suffered
from a high workload due to a global Ebola epidemic at the time of the experiments), and con-
sequently the limited number of FeverDisks that could be tested, resulting data was not suffi-
cient for a statistically significant clinical study. Therefore, the goal of this work was (i) the
demonstration of the capability of the newly-developed platform and its components to detect
as many of the aforementioned pathogens as possible, available in the samples that we had
access to; (ii) the proof-of-principle of fully automated sample-to-answer operation with mini-
mum hands-on time; and (iii) the analytical performance characterization of the platform. A
first test series was conducted at the Institut Pasteur in Dakar (IPD), Senegal (West Africa), fol-
lowed by a second test series at the Central Laboratory in Khartoum (CLK), Sudan (East
Africa). In both cases, biobanked samples were analyzed using the FeverDisk and were com-
pared to reference methods available at each site. Some bacterial pathogens which were not
available in biobanked samples, were used as cultured samples for specificity assessment (in
Dakar), and with varying spiked concentrations for limit of detection assessment (in the third
small-scale study in Reinfeld, Germany).
Materials and methods
Ethics statement
For the test series in Senegal and Sudan, samples used in the studies were part of the collections
of Institut Pasteur in Dakar and Central Laboratory Khartoum, respectively. Ethical approval
for retrospective use of the anonymized samples (acquired under informed consent) in diag-
nostic development research was available from the Ministry of Health of Senegal, as well as
from the Central Laboratory Ethical Committee and the Ministry of Higher Education and
Scientific Research in Sudan.
Sample cohorts and reference methods
Samples for the Senegal test series were acquired from retrospective studies and experiments
were carried out at the Virology Department of IPD, which is a WHO Collaborating Center
for Arboviruses and Haemorrhagic Fever Reference and Research. In particular:
The CHIKV samples (serum) were collected during the Senegal epidemic of 2015 in Kedou-
gou (southeastern region). They were stored at -80˚C and were tested at IPD by benchtop real-
time RT-PCR [29] and real-time RT-LAMP [30] as reference methods.
The DENV samples (supernatant of infected cells) were collected during epidemics out-
breaks in Senegal (2014) and Mauritania (2014). They were stored at -80˚C and were tested at
IPD by benchtop real-time RT-PCR [31] and real-time RT-LAMP [32] as reference methods.
The malaria samples (blood) were collected in Kedougou, as part of the local entomological
and human serosurveys program of febrile illness diseases, including malaria and main arbovi-
rus diseases. The program was dedicated to systematic surveillance of malaria, dengue and chi-
kungunya fever. These samples were aliquoted and stored at +4˚C for malaria tests. Reference
tests were done by microscopy, LFTs and PCR. For the latter, more details are available in
Niang et al [33].
The Salmonella Typhi and Paratyphi A samples were stool bacterial cultures and were tested
for the purpose of specificity assessment against the other pathogens’ primers of the FeverDisk.
Reference tests were done by standard microbiology diagnostic procedures, namely culture,
isolation, identification and antimicrobial susceptibility testing, according to the ISO 6579
standard. The extracted DNA using the QIAamp DNA Mini Kit, QIAGEN, Germany was
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quantified using the Nanodrop spectrophotometer instrument at the Bacteriology Department
of IPD. Further information on the preparation of the cultured samples are provided in section
A in S1 Text.
Malaria samples (whole blood) for the Sudan test series were acquired from retrospective
studies and experiments were carried out at CLK. Samples were stored at -20˚C before testing.
All samples were additionally tested with the reference methods available on site, i.e. micro-
scopic examination of thin and thick blood smears as well as benchtop LAMP.
In addition, during the test period, one patient presented with acute fever, sample (whole
blood) was collected in real-time following the required ethics conditions, and the sample was
tested immediately on site.
Nucleic acid extraction
Total nucleic acid extraction from raw samples was performed using a solid-phase extraction
kit based on Boom chemistry [34].
For the reference benchtop RT-PCR and RT-LAMP of the biobanked DENV and CHIKV
samples in IPD, RNA extractions were carried out using the QIAamp Viral RNA Mini Kit
(QIAGEN, Germany) following the supplier’s recommended protocol.
For the reference benchtop PCR of the biobanked malaria samples in IPD, genomic DNA
extraction of Plasmodium parasites was performed using the QIAmp DNA Mini Kit (QIA-
GEN, Germany) according to supplier’s protocol.
For the reference benchtop LAMP of the biobanked samples in CLK, DNA was extracted
using innuPREP MP Basic Kit A (art. # 845-KS-4900500, Analytik Jena GmbH, Germany).
Total nucleic acid extraction on the FeverDisk
For the FeverDisk experiments, silica coated magnetic beads (MagSuspension, from innuPREP
MP Basic Kit A, # 845-KS-4900500, Analytik Jena GmbH, Germany) were pre-stored in dry
format on the FeverDisk. The beads were combined with nucleic acid extraction buffers (Mag-
naMedics Diagnostics BV, currently magtivio BV, the Netherlands), pre-stored in the Fever-
Disk in stick-packs [35]. The custom-developed extraction protocol, which was automated on
the FeverDisk, was also performed manually as described in section B in S1 Text.
Protocol for manual nucleic acid amplification
For the real-time PCR based benchtop reference amplification of the malaria biobanked sam-
ples in IPD, Plasmodium spp detection as well as differentiation from CHIKV, DENV, YFV
and ZIKV was performed using multiplex real-time amplification and a nested PCR protocol
as previously described by Niang et al [33].
For the real-time RT-PCR based benchtop reference amplification of the CHIKV and
DENV biobanked samples at IPD, the protocols are described in Pastorino et al [29] and Wu
et al [31], respectively.
For the real-time RT-LAMP based benchtop reference amplification of the CHIKV and
DENV biobanked samples at IPD, RT-LAMP reagents (except primers) were the same for all
reactions. Total reaction volume was 25 μL for all reactions. RT-LAMP reactions were run at
64˚C using an ABI7500 Fast real-time PCR system (Applied Biosystems) according to Lopez-
Jimena et al [30,32]. All the tube assays conducted at the IPD were performed in triplicates,
with the exception of the sample 274755 that was tested in duplicates for DENV4.
For the real-time LAMP based benchtop reference amplification of the malaria biobanked
samples in CLK, LAMP was performed in 25 μL for all reactions including all reagents, primer
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sets and template. Reactions were run at 64˚C using a Rotor-gene cycler (QIAGEN, Germany)
and amplification time was 1 h.
For the real-time nucleic acid amplification on all the FeverDisk experiments, all reagents
needed for the LAMP amplification stage were pre-stored on the FeverDisk in lyophilized
form. Primers used for each target were dried in each reaction chamber. Lyophilized pellets
were developed and provided by MAST Group Ltd, UK.
LAMP primer design
Primer sets for the CHIKV and DENV1-4 virus targets were designed using a combination of
Principal Component Analysis (PCA) and LAMP primer design based on sequence align-
ments using the LAVA software [36]. DENV primer sets were based on full genome sequences
whilst CHIKV primer sets were designed on the same target region (6K-E1 region) [30,32].
Two different ZIKV assays were tested based on different primer design approaches [37].
One of the assays was developed following the methodology described by Lopez-Jimena et al
[32]. Briefly, it consisted of an open source approach, in which 45 whole genome ZIKV
sequences, covering strains from 1947 to 2015–2016, were retrieved from NCBI database, sub-
mitted to phylogenetic analysis, principal component analysis (PCA) and primer design using
LAVA software. The second developed ZIKV assay was based on standard software for LAMP
primer design (Primer Explorer V4), using 59 sequences of the ZIKV 3’ untranslated region
(UTR). Further in silico tests using VisualOMP (DNA software) discarded primer sets based
on primer dimerization and secondary structures.
For Plasmodium, Salmonella enterica Typhi and Paratyphi A, as well as Streptococcus pneu-
moniae (all designed at Mast Diagnostica GmbH), primer sets targeting specific regions of the
genome (18s and/or mitochondria for Plasmodium species, STY0201 for S. Typhi, SSPA2308
for S. Paratyphi A, and lytA and PsaA for S. pneumoniae) were designed using Primer Explorer
(http://primerexplorer.jp/e/).
Sample-to-answer operation of the FeverDisk and corresponding
processing device
For FeverDisk operation, the cartridge is placed into a LabDisk player 1 (ESMO01-MB-3044,
QIAGEN Lake Constance, Germany). The device features a customized holder for cartridge
fixation, stationary magnets for magnetic bead manipulation, as well as temperature and rota-
tional frequency control for microfluidic processing as presented in prior work [38]. In the
present study, fluorescence detectors allowed for detection of nucleic acid amplification prod-
uct in the green channel (FAM). The FeverDisk (Fig 1) can handle a sample volume of 200 μL.
The only manual steps to complete are sample addition and sealing of the inlet with a pres-
sure-sensitive adhesive foil. The LabDisk player 1 (Fig 2) executes the required operations in a
fully automated way until result acquisition. In short, this includes: Sample lysis, nucleic acid
binding to magnetic beads, two times washing of the nucleic acids followed by an elution step.
After nucleic acid extraction, the obtained eluate is mixed with lyophilized amplification
reagents (enzymes, salts, dNTPs, dye). Then, this mastermix is aliquoted into twelve reaction
chambers of 10 μL volume, each. Last, nucleic acids are amplified by LAMP and signal is
acquired in the green channel. Centrifugal microfluidics is advantageous in the present appli-
cation, since it provides liquid control by centrifugal force. The resulting fully automated anal-
ysis can be achieved without external pumps or tubes, for liquid handling. The system builds
up on so-called microfluidic unit operations [26,39]. Some advanced centrifugal microfluidic
unit operations that are used in this work in order to enable full automation are: (i) magnetic
bead transfer under continuous rotation during the extraction [40]; (ii) monolithic valves
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Fig 1. Photograph of a FeverDisk cartridge. All reagents are pre-stored for fully automated nucleic acid analysis. The sample inlet is sealed with a pre-
mounted sealing foil.
https://doi.org/10.1371/journal.pntd.0009177.g001
Fig 2. Photograph of the FeverDisk processing device. Dr. Cheikh Fall, co-author from the Institut Pasteur de Dakar, prepares a FeverDisk for
measurement.
https://doi.org/10.1371/journal.pntd.0009177.g002
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using temperature change-rate (TCR) actuated valving [41]; (iii) centrifugo-dynamic inward
pumping [42]; and (iv) dead-volume free and monolithic rehydration and mixing of the lyoph-
ilized LAMP reagent pellet using TCR-actuated bubble-mixing [43]. More details on the
microfluidic and temperature protocols and sequence of steps are given in S1 Fig and S1
Table. Details on the FeverDisk production are given in section C in S1 Text. Experiments
were performed on three devices at three different locations, namely in Dakar (Senegal), Khar-
toum (Sudan), and Reinfeld (Germany).
Data analysis
Fluorescence signals from FeverDisk experiments were analyzed to determine the time-to-pos-
itive (Tp) of the LAMP reactions using a custom script (Mathematica, Wolfram Research, Inc.,
UK) and following the procedures for data normalization and Tp calculation described in our
prior work [43]. Tp was defined as the time, where the normalized fluorescence signal reached
a threshold level of 20 standard deviations above the baseline allowing to reliably filter possible
noisy background. As control for microfluidic integrity, i.e. filling of read-out chambers, the
baseline signals of the raw data from FeverDisk experiments were required to be larger than
200 mV.
Results
FeverDisk results of the test series in Dakar, Senegal
The known positive biobanked samples were tested using either one or two FeverDisks per
sample, depending on the volume availability. An overview of disks and results is shown in
Table 1. The detailed results are provided in the following sections.
Detection of co-infections. Sample 274755, collected during a CHIKV epidemic in 2015,
CHIKV positive by benchtop real-time RT-PCR (Ct 25.30) and real-time RT-LAMP (Tp 16–17
min), was tested by one FeverDisk and yielded a true positive CHIKV signal, as well as an addi-
tional positive signal for DENV4 in chamber 12 (Fig 3). A subsequent benchtop real-time
RT-LAMP confirmed DENV4 (2/2) in this sample, which was therefore considered a true pos-
itive co-infection of CHIKV and DENV4.
Sample 274754, CHIKV positive by benchtop real-time RT-PCR (Ct 25.13) and real-time
RT-LAMP (Tp 16–17 min) was tested by one FeverDisk, which confirmed CHIKV presence
and yielded an additional amplification signal for DENV2 in chamber 10 (Fig 4). To verify the
DENV2 signal, the sample was tested in triplicate for DENV2 by benchtop real-time
RT-LAMP, which yielded 1/3 positives. Considering that the sample was diluted before use on
the FeverDisk (Table 1, 150 μL serum + 50 μL molecular grade H2O, instead of 200 μL serum,
due to lack of sufficient volume), the results from both, the benchtop and the FeverDisk
LAMP indicate that DENV2 co-infection was detected close to the limit of detection (LOD).
Sample 274443 was CHIKV positive by real-time RT-PCR (Ct 32.80) at the time of collec-
tion. When tested with two FeverDisks it provided CHIKV negative results (S2 Fig). Subse-
quent repetition of the real-time RT-PCR six months after collection (at the time of FeverDisk
experiments) yielded negative results, confirming the FeverDisk results. Most likely the viral
RNA in the sample had degraded. The benchtop real-time RT-LAMP gave positive amplifica-
tion between 30–35 min (2/3 repetitions), which indicates that the RT-LAMP managed to
amplify remaining non-degraded viral RNA, while being at the limit of detection, and possibly
being slightly more sensitive than the LAMP in FeverDisk, which explains why there was no
amplification by RT-PCR or the FeverDisk. In addition, this sample was found positive for Pf
and Pspp in both FeverDisk runs (S2 Fig). A subsequent benchtop malaria real-time PCR for
Pspp yielded a Ct value of 35.82, which confirmed the FeverDisk results.
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Table 1. Overview of results from the test series in Senegal where 29 FeverDisks were used. The reference methods as well as the FeverDisk results are shown.
Specimen details Reference methods FeverDisk test results in Senegal






























































































CHIKV Serum 29.28 CHIKV: 18–19 n/a n/a n/a - - FN
274438-B - - FN
274530-A Senegal,
2015
CHIKV 150 μL serum
+ 50 μL H2O d
33.22 CHIKV: 16–17 n/a n/a n/a - - FN
267197-A Senegal,
2014
DENV e Supernatant of
infected cells
25.89 DENV1: 20 n/a n/a n/a DENV1 41 TP
267175-B Maurita
nia, 2014
DENV e Supernatant of
infected cells





27.82 DENV2: 30–31 n/a n/a n/a DENV2 64 TP





26.15 DENV2: 28–29 n/a n/a n/a DENV2 - FN
267150-B DENV2 59 TP
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S. Typhi Stool culture n/a S. Typhi: n/a n/a n/a 109.9 S. Typhi 22 TP








S. Typhi Stool culture n/a S. Typhi: n/a n/a n/a 205.9 S. Typhi 15 TP




S. Paratyphi A Stool culture n/a S. Paratyphi A:
n/a
n/a n/a 116.2 S. Paratyphi A 31 TP




S. Paratyphi A Stool culture n/a S. Paratyphi A:
n/a
n/a n/a 395.0 S. Paratyphi A 53 TP
(Continued)
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Determination of unknown DENV serotype in biobanked samples. Two samples,
267197 and 267175 were characterized with benchtop RT-PCR as DENV positive (Ct 25.89
and 29.79, respectively) but of unknown serotype and were tested with one FeverDisk each.
The FeverDisk panel allowed to determine that both DENV samples were of serotype 1, as the
amplification signal appeared in chamber 9 where DENV1 primers were pre-stored (Fig 5).
Serotyping was confirmed by benchtop RT-LAMP [32].
Detection of single infectious pathogens. Several samples yielded FeverDisk results for a
single infectious agent (S3 Fig) and confirmed their corresponding reference method results
(Table 1).
Table 1. (Continued)
Specimen details Reference methods FeverDisk test results in Senegal

























S. Paratyphi A Stool culture n/a S. Paratyphi A:
n/a
n/a n/a 287.4 S. Paratyphi A 44 TP
a: The letters “A”, “B”, “C” next to the sample ID mean that there was one or more disks, respectively, tested with sample from the same vial.
b: Time-to-positive (Tp) ranges of benchtop LAMP results, representing triplicates, except 274755 that was tested in duplicate for DENV4. Between brackets there is
information about positive results obtained within the total of replicates.
c: Method not available.
d: Due to lack of sufficient material to run two disks, 50 μL molecular grade H2O were added to the 150 μL of sample.
e: Serotype determined by the FeverDisk and confirmed by the RT-LAMP.
f: The sample was deemed clotted and thus diluted with a small amount of PBS.
https://doi.org/10.1371/journal.pntd.0009177.t001
Fig 3. Detection of CHIKV and DENV4 co-infection in sample 274755. The FeverDisk showed a true positive DENV4 amplification in addition to
the CHIKV-expected amplification.
https://doi.org/10.1371/journal.pntd.0009177.g003
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Sample 267267, DENV2 positive by benchtop real-time RT-PCR (Ct 27.82) and real-time
RT-LAMP (Tp 30–31 min), was tested with two FeverDisks, both confirming this result as true
positive.
Sample 267150, DENV2 positive by benchtop real-time RT-PCR (Ct 26.15) and real-time
RT-LAMP (Tp 28–29 min) was positive in 1/3 FeverDisks and was considered positive close to
the limit of detection of the method.
Fig 4. Detection of CHIKV and DENV2 co-infection in sample 274754. The FeverDisk showed a true positive DENV2 amplification in addition
to the CHIKV-expected amplification.
https://doi.org/10.1371/journal.pntd.0009177.g004
Fig 5. Detection of DENV and determination of initially unknown serotype. Sample 267197 is shown here; sample 267175 showed similar results.
https://doi.org/10.1371/journal.pntd.0009177.g005
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Samples C71 and C74 were malaria (P. falciparum) positive by benchtop PCR (Ct 31.16 and
24.91, respectively). Two FeverDisks were used for each sample, and all four were true positive
for Pspp and Pf.
Samples S.12, S.15, S.16 and samples S.pT1, S.pT3, S.pT4 were provided as Salmonella
Typhi and Salmonella Paratyphi A stool cultures, respectively. Reference results were produced
by culture followed by DNA quantification using the Nanodrop spectrophotometer. All Fever-
Disks that were used with these samples confirmed the presence of the pathogen. Although
these were not clinical samples, we provide the results as additional data sets for the successful
fully automated FeverDisk operation and for the specificity of the other primers of the Fever-
Disk against the Salmonella samples.
False negative and negative results. Samples 274438 and 274530, CHIKV positive by
benchtop real-time RT-PCR (Ct 29.28, Ct 33.22) and real-time RT-LAMP (Tp 18–19 min, Tp
16–17 min), were not confirmed by two and one FeverDisks, respectively, which were consid-
ered to be false-negative results. However, due to limited available volume in sample 274530,
instead of 200 μL sample we added 50 μL molecular grade H2O to the available 150 μL sample,
which may have contributed to the negative result.
Sample B32 was tested with two reference methods and was found P. falciparum positive by
PCR (Ct 26.47) but negative by LFT (microscopy test had not been performed). LFTs have typ-
ically lower sensitivity than the PCR, therefore LFT was considered false negative. A negative
result in the one FeverDisk used was considered false negative, however again a dilution of the
sample had to be done as described above.
Sample 267207, DENV2 positive by benchtop real-time RT-PCR (Ct 38.48) and real-time
RT-LAMP (Tp 39–45 min) was negative in the one FeverDisk that was used. Considering the high
Ct and Tp values of the reference methods, it can be assumed that this sample was false negative by
FeverDisk because the RNA concentration was beyond the limit of detection of the method.
FeverDisk results of the test series in Khartoum, Sudan
A total of eight samples were made available during the Sudan test series (Table 2).
Samples #5, #6, #13, #14 and #20, positive by benchtop LAMP and microscopy, were tested
by one FeverDisk (sample #14 by two) and yielded true positive Pspp and Pf signals.
Sample #36 was malaria positive by benchtop LAMP but negative in microscopy. Contra-
dictory results between the two reference methods are due to the different sensitivities. Nucleic
acid amplification techniques have a higher sensitivity than microscopy. Also, microscopy is
based on visual inspection and depends on experience and subjectivity of the personnel.
Therefore, the one FeverDisk that was tested and yielded positive results for Pspp and Pf, is
considered true positive because it is in agreement with the more sensitive benchtop LAMP.
Sample #62, negative by benchtop LAMP and microscopy, yielded a negative signal in all
tested Plasmodium assays (Pspp, Pf, Pv) present in the panel of the one FeverDisk that was
tested. This is considered true negative as it is in accordance with the more sensitive among
the two reference methods (see comment above).
During the days of the tests, one patient presented with acute fever, and after clinical exami-
nation was found Pf positive based on microscopy. A blood sample (coded as “Sample X”,
Table 2) was taken and immediately tested in the FeverDisk, which yielded Pf and Pspp posi-
tive results (Fig 6).
FeverDisk results of the test series in Reinfeld, Germany
Given the limited availability of samples and no presence of bacteria in the biobanked samples
(except for the cultured samples), the authors performed a laboratory assessment of the
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analytical sensitivity of S. pneumoniae, S. Typhi and S. Paratyphi A by simultaneously spiking
known concentrations in 200 μL whole blood (see Table 3 and S4 Fig for the real-time amplifi-
cation curves). Twelve FeverDisks were used for S. Typhi, S. Paratyphi A and S. pneumoniae,
with 3 additional FeverDisks used for S. Paratyphi A only. The LOD with a 95% probability for
the three examined bacteria was calculated based on probit analysis, using Minitab 17 statisti-
cal software (Minitab Inc). The LOD for S. pneumoniae, S. Typhi and S. Paratyphi A was calcu-
lated 1394 CFU/mL, 1959 CFU/mL, and 25546 CFU/mL, respectively. The one order of
magnitude difference in the LOD of S. Paratyphi A is attributed to comparatively lower sensi-
tivity of the assay (see Table 3). The analytical sensitivity of the FeverDisk for P. falciparum
and the viral assays was not determined due to the insufficient resources and number of
FeverDisks.
Discussion
The need to cover the major differentials for fever of unknown origin in a tropical to subtropi-
cal setting is a daunting task, which is made even more challenging due to infrastructure issues
such as unstable provision of electricity or lack of refrigeration equipment for storage of diag-
nostic tests. In order to integrate sensitive, specific, rapid sample-to-answer testing of an essen-
tial panel of differentials in a user friendly way, the FeverDisk platform uses a microfluidic
disk to extract the total nucleic acid from samples in order to screen for 12 individual parame-
ters simultaneously in multiple distinct reaction chambers and using a point-of-care compati-
ble device. As our results show, this can lead to multiple detections and confirm co-infections
Table 2. Overview of results from the test series in Sudan where 9 FeverDisks were used. The reference methods as well as the FeverDisk results are shown.
Specimen details Reference methods FeverDisk test
results in Sudan
ID a Origin Confirmed/Expected
pathogen/infection
Sample #1: Benchtop LAMP
(Tp in min) b
#2: Microscopy
(pos/neg)
Pathogens detected Tp (in min) Result

















































































a: “A”, “B” next to the patient ID means that there was one or two disks, respectively, tested with sample from the same vial.
b; Time-to-positive (Tp) of LAMP results.
c: This is the fresh sample collected in real-time upon presence of a patient suspected with malaria after clinical examination.
https://doi.org/10.1371/journal.pntd.0009177.t002
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within a maximum of 2 h after the start of the automated analysis. The advantage is that the
individual reactions do not compete with one another and full analytical sensitivity is therefore
available for each parameter. The detection concept is qualitative (positive/negative output)
and the Tp value does not quantitatively correlate to the viral/bacterial/parasitic load. The goal
of the experiments was to demonstrate the proof-of-principle of the platform in operational
settings, with biobanked samples, as well as to assess the analytical performance. The rationale
behind the selection of the target pathogens was that: (i) they represent some of the main
fever-causing agents [20]; (ii) they cover three types of pathogens, namely parasites, bacteria
and viruses, therefore their differentiation is of crucial clinical utility and impact for down-
stream treatment; and (iii) DENV, CHIKV and ZIKV cover arboviruses co-circulating in the
Fig 6. Detection of malaria on a fresh whole blood sample collected in real time. Positive signal for Pf and Pspp was confirmed as true positive
with microscopy blood smear test.
https://doi.org/10.1371/journal.pntd.0009177.g006
Table 3. Bacterial concentrations tested in the FeverDisk to calculate the limit of detection and the ratio of posi-
tive results within the total repetitions assayed.
Bacteria CFU/mL Positive results/repetitions
S. Paratyphi (serotype A) 2×104 8/8
1×104 11/16
5×103 9/16
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same epidemic areas as malaria contributing to fever of unknown origin in Africa, but also in
Latin America and South East Asia [44–47].
Given that each FeverDisk integrates 12 assays, we characterize its performance on the
assay level. Thirty-eight biobanked samples tested by FeverDisk in both test series provided 59
assay results (40 in Senegal, 19 in Sudan; Pspp and Pf counted as individual assays, see Tables 1
and 2) out of which 51 were confirmed and in agreement with reference methods (32/40 in
Senegal and 19/19 in Sudan). This yields an 86.4% agreement between the FeverDisk- and ref-
erence method-confirmed assays. These results are sufficient to indicate the potential of the
platform.
Analytical performance of the FeverDisk
Each FeverDisk provides 12 LAMP assay results. Each sample containing a targeted pathogen
tested in a FeverDisk is expected to give at least one positive result from a chamber containing
the respective specific primers and up to 11 negative results, provided that the targeted organ-
ism concentration is within the detection limits of the respective assay. As shown in the test
series in Senegal, in some cases detection of co-infections are possible.
In this study, FeverDisk results were characterized as follows in comparison to reference
tests:
True positive (TP): positive in disk; confirmed positive by reference method
True negative (TN): negative in disk; confirmed negative by reference method
False positive (FP): positive in disk; negative by reference method
False negative (FN): negative in disk; positive by reference method
Negative (N): negative in disk; not tested by reference method
Case N refers to all (up to 12) negative results per FeverDisk, for which reference methods
were not done to verify the negativity, therefore they are characterized as “negative” and
not as “true negative”.
All positive FeverDisk results were confirmed by reference test results (Tables 1 and 2).
Mostly, more than one reference test was used and a considerable number of samples were
confirmed retrospectively after FeverDisk testing.
Interestingly, there were two cases that exhibited discrepancy between the reference meth-
ods. The Senegal sample B32, malaria positive by benchtop PCR, was LFT negative and Fever-
Disk negative. The Sudan sample #36, malaria positive by benchtop LAMP, was negative by
microscopy and FeverDisk positive.
In both cases, the molecular reference method, real-time PCR or real-time LAMP, was
more sensitive [48], and the FeverDisk results were characterized in reference to these molecu-
lar methods.
Definition of FeverDisk assay cut-off values and false positives. False positives are an
important factor influencing the specificity of a diagnostic detection platform and could lead
to unnecessary treatment. On the other hand, false negatives are very critical as they lead to
patients not receiving treatment. In order to properly determine clinical sensitivity and speci-
ficity, one would need a large collection of samples for statistical reasons including a significant
number of negatives (characterized with a reference method), which were not available in our
studies in Senegal and Sudan.
Nevertheless, we attempted to define the cut-off values which can be fine-tuned in future
work. Any isothermal amplification, if it runs for too long, will produce unspecific results due
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to primers’ tendency to self-hybridization [49] and therefore cut-offs have to be determined.
In preceding work, different cut-off limits were set for the benchtop CHIKV and DENV
LAMP assays [30,32]. Although we used the same primers, the FeverDisk assay is a different
test with different components and conditions (dried primers, lyophilized amplification
reagents, in situ extraction). Therefore, the cut-off had to be assessed separately for the Fever-
Disk. Indeed the viral RT-LAMP assays with low concentrations of primers needed longer run
times and generated false positives much later, than DNA-detecting assays for Plasmodium
and bacterial assays with higher primer concentrations and shorter run time. Each assay on
the FeverDisk had a distinct presumptive cut-off value [50] and the assays were divided into
three groups namely the Plasmodium, the bacterial, and the viral assays as described below.
Among the Plasmodium assays that were found positive (Pspp and Pf), the Pf assay is the
slowest based on experimental data. The highest Tp result for Pf among all tested FeverDisks
was at 40 min (sample 274443-A, Table 1), which corresponded to a benchtop PCR Ct of
35.82. Such high Ct values are typical at a concentration close to the limit of detection, there-
fore a Tp of 44 min is considered as the cut-off value for all Plasmodium assays (a 10% increase
in 40 min was considered; this 10% increase covers a 3-fold standard variation).
For the bacterial assays, given the fact that there were no bacteria-containing patient sam-
ples available at the biobanks, but only bacterial cultures, we used spiked samples in order to
demonstrate the integrated assay performance and define the LOD (Table 3). Consequently
we did not have FP in these samples. Therefore, for the purpose of this work, we state that the
cut-off time is the assay runtime itself, i.e. 60 min, derived from the benchtop assays. This can
be fine-tuned in the future when true bacteria positive samples will be tested.
For the CHIKV and DENV viral assays, the criterion is the appearance of CHIKV and
DENV4 at Tp 64 min in sample S.16-A (disk #10, Table 1), which was a clear false positive as
the sample was from an S. Typhi culture and therefore impossible to include any other target.
This Tp value was therefore set as a cut-off value for all CHIKV and DENV assays. For the
ZIKV LAMP, a cut-off value was not determined due to the lack of FeverDisk-positive samples
that would be needed to define the FP. Nevertheless, we used, as an approximate guidance, the
value of 45 min that was derived by Lopez-Jimena et al from benchtop ZIKV LAMP assays
[37].
In case of suspected miscalculation of the Tp by the algorithm, the real-time amplification
curves and/or confirmatory experiments were used in order to derive the true positive/nega-
tive results. The only two cases where this was needed were: (i) sample 274754 (Fig 4), where a
late amplification curve for DENV2 co-infection appeared and would be considered negative
according to the algorithm (Tp> 65 min). However, because it was very late, it had not had
enough time to reach the plateau phase and therefore the intensity of the fluorescence was not
high enough to be quantified by the algorithm that we used. Furthermore, a benchtop LAMP
for DENV2 confirmed the FeverDisk result as true positive. (ii) Sample 267175 where the Tp
for Pspp was calculated by the algorithm to be 55 min, was considered a true negative due to
the amplification curve drift which was miscalculated by the algorithm. Also, all positive viral
assays below this Tp were confirmed true positive with reference methods.
Overall, the results from Senegal and Sudan revealed that in terms of assay speed, the
malaria assays (Pspp and Pf) were the most rapid in the benchtop results as well as the Fever-
Disks, while the DENV2 was the slowest with both methods. Thus, to encompass all cut-off
values all graphs in this manuscript are set to 65 min and a summary of the false positives is
given in Table 4.
False negative results. Regarding the FN results (8/59 cases), some assumptions and pos-
sible explanations are expressed below.
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In two FeverDisk cases, 274530 and B32, that 200 μL of the sample was not available for the
disk, 50 μL molecular grade water and 50 μL PBS, respectively, were added to 150 μL of the
sample, and the results were FN on the disk. However, in three other FeverDisk cases (one for
274754 and two for C71), when the same dilution had to be done, the results were TP on the
disk. Therefore, the impact of the dilution factor of 3/4 sample and 1/4 water or buffer for the
FN samples can be regarded as negligible.
Because we performed regular quality control evaluation of the reagents before integration
into the FeverDisk, the possibility of reagent failure is unlikely. Especially in terms of RNA-lyo-
pellet stability, preliminary accelerated long-term storage tests of the lyopellets were performed
at 99% humidity and 50˚C temperature for 12 weeks, which corresponds to stability of 5.6
years storage at 4˚C or 1.6 years at 22˚C. The tests were done with RT-lyopellets and primers
targeting DENV1 virus to test cold chain independence for the transfer of the cartridges to
African settings.
The above show that the most likely explanation for the false negatives was the concentra-
tion of the pathogen being below the detection limit of the method. A spiked internal control
(IC) was not used in the current study but will be included in an extra chamber in the next
step of the development. Positive and negative controls for all individual assays were not
included nor required for closed diagnostic cartridge system like the FeverDisk, according to
the RiliBÄK (Richtlinien der Bundesärztekammer) [51].
Epidemics and diagnostic value
In cases of epidemics, caused by vector-borne diseases, the acute fever symptom overlaps with
that of endemic diseases. Given the sudden and massive nature of arbovirus epidemics, there is
a tendency to screen only for the epidemic-specific pathogen. Consequently, symptomatic
treatment of the epidemic fever may fail to address other possible underlying disease(s) and
specific treatment may not be offered at all.
In the 2014 Ebola epidemic about 90% of suspected cases matching the case definition were
tested negative for Ebola virus. However, the cause of their fever was not determined due to
lack of provision of testing for differentials [52]. In another study it was clearly shown that a
sudden DENV epidemic in Tanzania overlapped with endemic malaria in 2014 [53]. Especially
Table 4. FeverDisk false positive results. The results are considered as such, when the Tp values are higher than
those that were specified, i.e. Tp> 44 min for the Plasmodium assays; Tp> 60 min for the bacterial assays; Tp> 64 min
for the CHIKV, DENV viral assays.
Sample Confirmed pathogen with
reference method
Other pathogens that were found false positive with the FeverDisk
and their corresponding LAMP Tp (min)
C74-B Malaria DENV2 (93)
274755-A CHIKV Pspp (71)
274438-B CHIKV DENV2 (91)









a: Primer-design approach by Phylogeny, Principal Component Analysis and LAVA
https://doi.org/10.1371/journal.pntd.0009177.t004
PLOS NEGLECTED TROPICAL DISEASES FeverDisk platform for acute febrile illness
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009177 February 25, 2021 17 / 24
during the 2015–2016 ZIKV outbreak, there were urgent requests for combined tests to differ-
entially diagnose DENV, CHIKV and ZIKV fevers because all these three diseases exhibit very
similar clinical symptoms [54,55].
The FeverDisk demonstrated the ability to detect double infections in samples from a chi-
kungunya epidemic in Senegal in 2015, namely co-infections of CHIKV with DENV2 (sample
274754) and CHIKV with DENV4 (sample 274755). In the case of sample 274443, (which was
expected CHIKV-positive but had undergone RNA degradation between collection and testing
time), a co-infection with P. falciparum malaria, which had been missed by the routine
CHIKV analysis during the epidemic in 2015, was additionally detected by the FeverDisk, thus
highlighting the impact that this system can have. Additionally, the LabDisk responded suc-
cessfully to the spiking of three bacteria simultaneously in order to define their LOD as a “sim-
ulated” condition of co-infections. These examples clearly demonstrate that diagnostic tools
with multiple parameter detection capability, like the FeverDisk, have the unique advantage to
detect endemic and epidemic pathogens simultaneously and therefore can help to improve
decisions for suitable treatment.
Furthermore, the FeverDisk proved to be a useful tool for virus serotyping, as shown by the
DENV1 results for samples 267175 and 267197. By including the specific primer sets for
DENV1-4 in four reaction chambers, one experimental run was sufficient to determine the
DENV serotype. The approach to detect the DENV types individually guarantees that all of the
documented variation of DENV genomes is covered [32]. Although this is in principle not
necessary for patient management and therapy prescription, it is important for epidemiologi-
cal and entomological studies and mapping of prevalences [56]. Similarly, for species identifi-
cation of Plasmodium, the fact that the FeverDisk is capable of detecting multiple targets
allows the inclusion of individual Plasmodium-specific primers, as well as the pan-malaria,
Plasmodium species (Pspp) assay. It was shown in this work that in total 14 FeverDisks were
true positive for malaria at both test sites, and the Pspp assays were always concordant with the
Pf assay. Thus, the FeverDisk platform could support comprehensive data acquisition for vec-
tor-borne pathogens (Plasmodium, DENV, CHIKV, ZIKV) [57,58].
Adaptability and universality of platform components
The Senegal primer panel of the FeverDisk was extended to include ZIKV [37] in the Sudan
test series (Table 2) in response to the large outbreak in Latin America and Africa. A ZIKV
positive sample was not determined by the FeverDisk (ZIKV negativity was not confirmed by
benchtop RT-PCR or RT-LAMP) but this change in the Sudan test panel demonstrates the
adaptability of the platform, keeping the cartridge design and non-specific reagents (extraction
kit and reaction mix lyopellet), while changing only the primer panel. Furthermore, this adapt-
ability was also shown when performing the LOD characterization using three simultaneously
spiked bacteria, in which case the panel was modified to have four times the primers of the
three bacteria (thus filling 12 reaction chambers).
The extraction reagents as well as the lyophilized amplification reagents were proven to be
of universal functionality, as they were compatible with parasites and viruses (tested in Senegal
and Sudan), as well as bacteria (tested during the bacterial LOD experiments in Germany).
In terms of specimens, the FeverDisk was shown to be compatible with several sample
matrices, such as whole blood, serum, supernatant of infected cells, stool culture (even mixture
of serum/molecular grade water, whole blood/PBS). This feature is very important for a system
used as a platform aiming to be applied in a broad range of different laboratories/settings,
which may have different collection methods and sample types.
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Usability assessment and feedback by end-users for future outlook
The LabDisk has been used in the past for the detection of either only bacteria or only viruses
[38,59]. In other cases, only reduced versions of the disk had been tested for tropical infections,
namely Rift valley fever virus [60] and Yellow fever virus [61] including either extraction or
amplification units but not using pre-stored reagents. The test series in Senegal and Sudan
constituted the first time a fully integrated sample-to-answer LabDisk was used in Africa with
pre-stored and universal reagents suitable for bacteria, viruses, and parasites detection in sin-
gle- or co-infection configuration and with the ability to handle different sample matrices.
This can open the way for automated analysis of samples, without the need for manual sample
handling, thereby reducing the time to result and possible handling errors. The platform is
also suitable for remote settings/sentinel sites due to its low power consumption requirements
(isothermal amplification instead of thermocycling) [62–64] and cold chain independence.
One objective of the demonstration experiments was to assess the training requirements
and acquire feedback from the end-users regarding usability assessment. Using images and
video materials, as well as hands-on execution, the training was completed within two days
and included disk handling, mounting on the processing device, and the use of the device soft-
ware. The users commented on the usefulness of the FeverDisk in terms of its automation and
multi-target testing capability. The compatibility with several different sample matrices
(serum, whole blood, supernatant of cells, bacterial cultures) was also marked as an advantage.
The recommendations from the end-users, which can be used as an outlook by the develop-
ers, concerned the user-friendliness of the software interface and the use of alternative power
sources, e.g. battery or solar panel driven device, as electricity cuts affected some experimental
results. Furthermore, it was strongly recommended to develop a library of FeverDisks/panels
tailored to different geographic, endemic and epidemic needs. From this perspective, the
exchangeability of primers, as demonstrated in the three small scale studies, is of advantage.
Candidate next assays to be developed and integrated include those for tuberculosis, encephali-
tis, meningitis and leptospirosis, as well as for West Nile virus and Yellow fever virus. On the
assay development level, there is further room for improvements. Due to the fact that the cur-
rent disk design uses up the space of a whole disk for one patient sample, a next generation of
FeverDisks can explore the use of mechanical sample lysis (crude lysis) followed by direct
amplification. This could save space on disk, so that eventually two or three patients’ samples
could be tested simultaneously on one disk. In the light of recent improvements to deriving
quantitative information from isothermal amplification curves [65] it would be worth explor-
ing the capabilities of LAMP technology in order to provide quantitative, or at least semi-
quantitative information that could potentially correlate the amplification results with the
pathogen load. This could assist in accurate monitoring of patients during the administration
of antimicrobial treatment.
Naturally, the cost was one topic that was discussed with the end-users. Given the late-stage
development of the platform there is no available information on its transfer price. However,
the technology developers have identified the cost-driver mechanisms and ways to overcome
them, for example by using improved lyophilization methods, or transferring the cartridge
manufacturing method from thermoforming of polymer foils to injection molding. In any
case, the pricing of the proposed approach should not be compared against simple LFTs
because the level of information and consequently the diagnostic value that they offer is quite
different. Although a thorough cost/impact and health economics analysis needs to be done, it
can be easily deduced that the fully automated nature of the proposed approach offers a com-
petitive advantage against benchtop manual approaches in terms of “hidden” personnel costs
that are spent for performing multiple extractions and amplifications. Overall, as the cost is
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also a function of the number of targets for which the test is dedicated, it is expected that the
cost per target pathogen will be more competitive than the one in currently marketed systems
[20].
Next steps will include a reproducibility and production robustness analysis of the Fever-
Disk cartridges. Consequently, the system will be tested in a prospective study, with recruited
patients ideally in settings with different endemic and epidemic profile, including several well-
characterized negative samples, in order to determine the clinical sensitivity and specificity as
well as the positive/negative predictive value of the platform. In these studies we will also com-
pare the FeverDisk performance with fresh versus biobanked samples. Given the fact that the
system is capable of providing multiple target results, a clinical algorithm interface that can
offer decision support for the clinician is deemed necessary. Such an algorithm, in combina-
tion with the ability to distinguish viral from bacterial infections, could be an added value in
management of antimicrobial resistance.
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